Possibly, dysregulated mTOR signaling is a common pathologic event among cardiomyopathies of different etiology, as suggested by other reports of studies in mammalian cardiomyopathy models, and mTOR inhibition is a common therapeutic strategy (McMullen et al., 2004; Marin et al., 2011; Ramos et al., 2012; Sciarretta et al., 2018). This evidence concerns the gene MTOR and cardiomyopathy.